Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm

7Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Importance: COVID-19 vaccine-derived antibodies in pregnant people may protect infants from severe infection in the first 6 months of life via transplacental antibody transfer. Few data exist on maternally derived SARS-CoV-2 antibodies in preterm compared with full-term infants in association with vaccination timing. Objective: To compare SARS-CoV-2 anti-Spike (anti-S) antibody levels in preterm and full-term infants in the context of vaccine dose timing before delivery. Design, Setting, and Participants: This prospective cohort study enrolled pregnant individuals and collected paired maternal and cord blood samples at delivery at the University of Washington between February 1, 2021, and January 31, 2023. Participants who had received at least 2 doses of a messenger RNA COVID-19 vaccine before delivery and did not have a history of prior COVID-19 infection or detectable anti-SARS-CoV-2 nucleocapsid antibodies were included. Exposures: Timing of the last vaccine dose and preterm or full-term gestational age at delivery. Main Outcomes and Measures: Paired maternal and cord samples were tested for anti-S antibody, and linear regression was used to evaluate associations between preterm delivery and anti-S antibody levels. Covariates included timing of last dose, number of doses, insurance status, and immunosuppressing medications. Results: A total of 220 participants (median [IQR] age, 34 [32-37] years; 212 [96.4%] female) with 36 preterm and 184 full-term deliveries were studied. Before delivery, 121 persons received 2 vaccine doses and 99 persons received 3 or more vaccine doses. The geometric mean concentration of maternal anti-S antibodies was 674 (95% CI, 577-787) after 2 doses and 8159 (95% CI, 6636-10032) after 3 or more doses (P

References Powered by Scopus

Update: Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020

979Citations
N/AReaders
Get full text

New intrauterine growth curves based on United States data

732Citations
N/AReaders
Get full text

Association between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

501Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

3Citations
N/AReaders
Get full text

Evaluation of Transplacental Maternal SARS-CoV-2 Antibody Transfer in Small for Gestational Age Infants

1Citations
N/AReaders
Get full text

Research Priorities for Maternal Immunization

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kachikis, A., Pike, M., Eckert, L. O., Roberts, E., Frank, Y., Young, A. L., … Englund, J. A. (2024). Timing of Maternal COVID-19 Vaccine and Antibody Concentrations in Infants Born Preterm. JAMA Network Open, 7(1), E2352387. https://doi.org/10.1001/jamanetworkopen.2023.52387

Readers over time

‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 1

25%

Biochemistry, Genetics and Molecular Bi... 1

25%

Sports and Recreations 1

25%

Arts and Humanities 1

25%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 11
Social Media
Shares, Likes & Comments: 23

Save time finding and organizing research with Mendeley

Sign up for free
0